Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–140 of 140 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combined Oral Contraceptive Clear all

Conditions: Contraception
Interventions: Desogestrel and Ethinyl Estradiol Tablets; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Hepatitis B
Interventions: ABI-H2158, Itraconazole, Rifampin, Midazolam, Ethinyl Estradiol / Levonorgestrel, Esomeprazole, Placebo matching oral contraceptive; Drug
Lead sponsor: Assembly Biosciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Contraception Behavior
Interventions: Ethinyl Estradiol / Norgestimate Oral Tablet; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 23 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Labor Pain
Interventions: Fentanyl 20 mcg, Fentanyl 100 mcg; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Temporomandibular Joint Disorders
Interventions: Self Management, Targeted Self Management, 20 mcg ethinyl estradiol and 100 mcg levonorgestrel; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hemostasis, Oral Contraceptive
Interventions: 91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive; Drug
Lead sponsor: Teva Women's Health; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 265 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 21
States / cities: San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more

Conditions: Healthy Participants
Interventions: BMS-986322, Loestrin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Anaheim, California

Conditions: Healthy Volunteer
Interventions: Ethinyl Estradiol + Levonorgestrel, ABBV-722; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Uterine Hemorrhage, Contraception
Interventions: Combined Oral Contraceptive Pill, Placebo Sugar Pill; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Volunteers
Interventions: Zasocitinib, COC, Metformin, Digoxin, Esomeprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: HIV Infections
Interventions: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Diego, California

Conditions: Chronic Hepatitis C
Interventions: BMS-790052, Ortho Tri-Cyclen®; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tempe, Arizona • Austin, Texas

Conditions: HIV Infections
Interventions: Ethinyl estradiol/levonorgestrel, Medroxyprogesterone acetate; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 6,360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Healthy Volunteer
Interventions: PTI-428, Placebo, ethinyl estradiol and levonorgestrel; Drug · Other
Lead sponsor: Proteostasis Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin, Oral combined hormonal contraceptives; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 40 Years to 49 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Polycystic Ovary Syndrome
Interventions: 3 mg DRSP/20 μg EE; Drug
Lead sponsor: Woman's; Other
Eligibility: 16 Years to 35 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: HIV
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 20 Years to 40 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Anorexia Nervosa
Interventions: Hormone replacement therapy (estrogen/progestin), Placebo (Sugar Pill), Dehydroepiandrosterone (DHEA); Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 15 Years to 30 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Contraception
Interventions: NOMAC-E2 COC; Drug
Lead sponsor: Organon and Co; Industry
Eligibility: 14 Years to 35 Years · Female only
Enrollment: 3,055 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 103
States / cities: Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 79 more

Conditions: Contraception
Interventions: Relugolix Combination Therapy; Drug
Lead sponsor: Sumitomo Pharma Switzerland GmbH; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 109
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 89 more

Search by objective public record fields.

Desogestrel-containing COCP Pharmacokinetic Validation Study

A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults

Premature Discontinuation of Contraceptive Implants

Epidural Fentanyl for 2nd Stage Labor Analgesia

Managing Temporomandibular Disorder (TMD) Symptoms

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants

A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants

Does Concomitant Use of Combined Oral Hormonal Steroids Stop Bleeding in Women Using Etonogestrel Implants (Implanon/Nexplanon®)?: A Randomized Controlled Study

A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

Hormonal Birth Control and the Risk of Acquiring HIV

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

Relative Desirability of Metformin vs. Birth Control Pill in Treating PCOS in Women of Later Reproductive Age

Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism

Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and Raltegravir

Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa

Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive

Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy